Imexpharm

Imexpharm EBIT Margin

The EBIT Margin (Operating Margin) of Imexpharm (IMP.VN) as of Oct 26, 2026 is 18.94 %. In the previous year, EBIT Margin (Operating Margin) was 18.83 % — a change of 0.60% (higher).

EBIT Margin

18.94 %

YoY

0.60%

Last updated:

EBIT Margin (Operating Margin) of Imexpharm is 2025 18.94 % . EBIT Margin (Operating Margin) of Imexpharm was 2024 18.83 % . It decreases by 0.60% higher compared to the previous year.

Imexpharm's operating (EBIT) margin stands at 18.9%, broadly stable from 19.5% several years earlier.

The Imexpharm EBIT Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT Margin
Date
EBIT Margin
Jan 1, 2018
13.37 VND
Jan 1, 2019
14.48 VND
Jan 1, 2020
19.17 VND
Jan 1, 2021
19.54 VND
Jan 1, 2022
18.04 VND
Jan 1, 2023
19.11 VND
Jan 1, 2024
18.83 VND
Jan 1, 2025
18.94 VND
The Imexpharm EBIT Margin history
YEAREBIT MarginYoY
18.94 %+0.60%
18.83 %-1.45%
19.11 %+5.93%
18.04 %-7.66%
19.54 %+1.89%
19.17 %+32.43%
14.48 %+8.30%
13.37 %+20.68%
11.08 %-6.24%
11.81 %+7.14%
11.03 %-2.72%
11.34 %+10,661.19%
0.11 %-12.24%
0.12 %-10.69%
0.13 %+4.95%
0.13 %+0.52%
0.13 %+0.13%
0.13 %+1.69%
0.13 %+40.52%
0.09 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Imexpharm Stock analysis

What does Imexpharm do? Imexpharm Corp manufactures and trades pharmaceuticals, medicinal chemicals, and botanical products, including antiseptics, traditional medicine, medical equipment, cosmetics, and supplemental food and drinks. The company provides packaging and warehousing services specifically for pharmaceutical storage. It also cultivates medicinal herbs. Imexpharm Corp serves the pharmaceutical industry and healthcare sector through its manufacturing, import, export, and trade operations, targeting businesses requiring medicinal products and services. The company's revenue streams include the sale of manufactured pharmaceuticals, imported and exported goods, and services such as packaging and warehousing. Its customers are businesses in the healthcare sector, including distributors and retailers of pharmaceuticals, medical equipment, and related products. The firm's operations span manufacturing, import, export, and trade, with additional services supporting the pharmaceutical supply chain. Imexpharm Corp's product portfolio covers a wide range of medicinal and health-related items, from antiseptics to supplemental food and drinks. The company's involvement in medicinal herb cultivation supports its production of traditional medicine and herbal-based products. This vertical integration enhances its ability to supply comprehensive solutions to healthcare businesses. Imexpharm is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Imexpharm stock

EBIT Margin (Operating Margin) of Imexpharm is 18.94 % in 2025.

EBIT Margin (Operating Margin) of Imexpharm changed from 18.83 % to 18.94 %, representing a 0.60% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBIT Margin (Operating Margin) Imexpharm since 2006 – with annual values, charts, and detailed analysis.

EBIT Margin measures operating profitability as a percentage of revenue. It shows how much profit a company makes from operations before interest and taxes.

A 'good' varies by industry and company stage. On Eulerpool, you can compare EBIT Margin (Operating Margin)'s Imexpharm with sector peers and the industry average to assess whether it is attractive.

To evaluate EBIT Margin (Operating Margin)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EBIT Margin (Operating Margin).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Margins — Imexpharm

Gross MarginEBIT MarginEBITDA MarginNet MarginFCF MarginR&D / RevenueTax RatePayout RatioPre-Tax MarginOCF MarginSGA/RevenueOpEx/RevenueReinvestment Rate

All Key Metrics — Imexpharm